- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06918561
Évaluation de l'efficacité du néothélium ft dans le traitement des plaies ouvertes chroniques
Évaluation de l'efficacité du néothélium ft dans la guérison des plaies ouvertes chroniques: un essai multicentrique contrôlé randomisé
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Angelina Ferguson, DNP
- Numéro de téléphone: (985) 629-4013
- E-mail: info@sygnola.com
Sauvegarde des contacts de l'étude
- Nom: Sarah Moore, MBE
- Numéro de téléphone: (985) 629-4013
- E-mail: info@sygnola.com
Lieux d'étude
-
-
Louisiana
-
Denham Springs, Louisiana, États-Unis, 70726
- Recrutement
- MedCentris of Denham Springs
-
Chercheur principal:
- Monique Consoer, NP
-
Contact:
- Tabatha Yent
- E-mail: tabatha.yent@medcentris.com
-
Hammond, Louisiana, États-Unis, 70403
- Recrutement
- MedCentris of Hammond
-
Chercheur principal:
- Chris Keaton, NP
-
Contact:
- Chelsea Smith, RN
- E-mail: Chelsea.smith@medcentris.com
-
Contact:
- Melanie Knox, LPN
- E-mail: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, États-Unis, 70507
- Complété
- MedCentris of Carencro
-
Leesville, Louisiana, États-Unis, 71146
- Recrutement
- MedCentris of Leesville
-
Chercheur principal:
- Stefanie Corley, FNP
-
Contact:
- Brandi Shuff
- E-mail: Brandi.shuff@medcentris.com
-
Many, Louisiana, États-Unis, 71449
- Recrutement
- MedCentris of Many
-
Chercheur principal:
- Stefanie Corley, FNP
-
Contact:
- Brandi Shuff
- E-mail: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, États-Unis, 71351
- Recrutement
- MedCentris of Marksville
-
Chercheur principal:
- Averie Rachal, FNP
-
Contact:
- Laura Whittington
- E-mail: Laura.whittington@medcentris.com
-
Metairie, Louisiana, États-Unis, 70001
- Recrutement
- MedCentris of Metairie
-
Contact:
- Ninya Powell
- E-mail: ninya.powell@medcentris.com
-
Chercheur principal:
- Sarah Logrande, NP
-
Minden, Louisiana, États-Unis, 71055
- Recrutement
- MedCentris of Minden
-
Chercheur principal:
- Taheera Forbes, NP
-
Contact:
- Brianna Thompas
- E-mail: brianna.thompson@medcentris.com
-
Monroe, Louisiana, États-Unis, 71201
- Pas encore de recrutement
- MedCentris of Monroe
-
Chercheur principal:
- Libbi Trawick, NP
-
Contact:
- Tiffany Dew
- E-mail: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, États-Unis, 70458
- Recrutement
- MedCentris of Slidell
-
Chercheur principal:
- Katie Schloegel, FNP
-
Contact:
- Donyille Singletary, RN
- Numéro de téléphone: 985-602-1215
- E-mail: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, États-Unis, 39540
- Complété
- MedCentris of D'iberville
-
McComb, Mississippi, États-Unis, 39648
- Complété
- MedCentris of McComb
-
Natchez, Mississippi, États-Unis, 39120
- Complété
- MedCentris of Natchez
-
Southaven, Mississippi, États-Unis, 38671
- Recrutement
- MedCentris of Southaven
-
Chercheur principal:
- Carlene McAllister, NP
-
Contact:
- De'Nyia Woods
- E-mail: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, États-Unis, 11234
- Recrutement
- Northeast Podiatry Consultant
-
Contact:
- Thomas Hayes
- E-mail: thomas@simonfootandankle.com
-
Chercheur principal:
- David Simon, DPM, FACFAS
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Expérimental: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Complete Wound Closure
Délai: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage Wound Area Change
Délai: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Délai: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Follow-Up Closure
Délai: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Délai: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Délai: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Angelina Ferguson, DNP, SygNola, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HEAL
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .